Imprida
amlodipine / valsartan
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Imprida has been withdrawn at the request of the marketing authorisation holder.
This EPAR was last updated on 11/05/2017
Authorisation details
Product details | |
---|---|
Name |
Imprida
|
Agency product number |
EMEA/H/C/000775
|
Active substance |
|
International non-proprietary name (INN) or common name |
|
Therapeutic area (MeSH) |
Hypertension
|
Anatomical therapeutic chemical (ATC) code |
C09DB01
|
Publication details | |
---|---|
Marketing-authorisation holder |
Novartis Europharm Ltd
|
Revision |
20
|
Date of issue of marketing authorisation valid throughout the European Union |
17/01/2007
|
Contact address |
Product information
03/04/2017 Imprida - EMEA/H/C/000775 - WS/0709
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Agents acting on the renin-angiotensin system
Therapeutic indication
Therapeutic indication
Treatment of essential hypertension.
Imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
Assessment history
News
-
28/06/2013
-
17/05/2013
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 201121/10/2011
-
20/10/2011
-
24/04/2008